LYUDMILA CHEBAN: Open Payments
NPI 1336579580 · ORMOND BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$917 in 49 payments from 17 companies in 2025. Trend: 2023 $1,125 · 2024 $1,482 · 2025 $917
Food & beverage: $917
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $211 |
| Lilly USA, LLC | 7 | $142 |
| Novo Nordisk Inc | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Radius Health, Inc. | 2 | $56 |
| Exact Sciences Corporation | 3 | $55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| ABBVIE INC. | 2 | $34 |
| Amgen Inc. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
Products named: TRELEGY ELLIPTA, REXULTI, MOUNJARO, JARDIANCE, The Cologuard Plus Collection Kit, Ozempic, Wegovy, XIFAXAN.
Industry payments across FL — which companies pay providers there.
